List of Excipients in Branded Drug ISTALOL

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch & Lomb Incorporated	ISTALOL	timolol maleate	24208-004	BENZALKONIUM CHLORIDE
Bausch & Lomb Incorporated	ISTALOL	timolol maleate	24208-004	POTASSIUM SORBATE
Bausch & Lomb Incorporated	ISTALOL	timolol maleate	24208-004	SODIUM CHLORIDE

Istalol Excipient Strategy and Commercial Opportunities

Last updated: October 11, 2026

Istalol is a once-daily, 0.5% timolol maleate ophthalmic solution for reducing elevated intraocular pressure in ocular hypertension and open-angle glaucoma. Its commercial differentiation depends less on the active ingredient, which is widely genericized, and more on preservative selection, ocular tolerability, multidose packaging, device performance, and adherence positioning.

The core opportunity is a lower-irritation timolol product that preserves once-daily dosing while avoiding the cost and complexity of a new chemical entity or biologic. The principal risk is price compression from generic timolol maleate ophthalmic solutions and limited willingness among payers to reimburse a premium for excipient-based differentiation.

What is Istalol and how is it formulated?

Istalol contains timolol maleate equivalent to timolol 0.5% in an aqueous ophthalmic solution. The product is administered once daily, generally as one drop in the affected eye or eyes. The labeled inactive ingredients include potassium sorbate, sodium citrate dihydrate, sodium phosphate dibasic, sodium hydroxide, and purified water. The formulation is buffered and adjusted to an ophthalmically acceptable pH range.[1]

Attribute	Istalol
Active ingredient	Timolol maleate
Strength	0.5% ophthalmic solution
Dosage form	Sterile aqueous eye drops
Indications	Ocular hypertension; open-angle glaucoma
Dosing	Once daily
Preservative	Potassium sorbate
Buffer system	Sodium citrate and sodium phosphate
Regulatory pathway	FDA NDA
FDA application	NDA 021455
Primary commercial distinction	Once-daily dosing and non-benzalkonium preservative strategy

Timolol is a nonselective beta-adrenergic antagonist. It lowers intraocular pressure by reducing aqueous humor production. The molecule has long been available in ophthalmic products, including generic timolol maleate and timolol hemihydrate formulations.

What excipients protect Istalol’s commercial position?

Potassium sorbate is the most commercially relevant excipient in the Istalol formulation. It provides antimicrobial preservation without using benzalkonium chloride, the preservative most commonly associated with chronic ophthalmic products.

Potassium sorbate

Potassium sorbate can support a positioning strategy focused on ocular-surface tolerability. Benzalkonium chloride has been associated with ocular-surface toxicity, tear-film disruption, epithelial effects, and increased concern in patients receiving chronic glaucoma therapy or using multiple preserved eye drops.[2]

The commercial value of potassium sorbate depends on four factors:

1. Demonstrated preservative effectiveness under USP <51> or the applicable regulatory standard.
2. Stability across the product shelf life.
3. Acceptable local tolerability in chronic use.
4. Reliable antimicrobial protection in a multidose container.

Potassium sorbate is not automatically superior for every patient. It can create formulation challenges involving pH, preservative activity, container compatibility, and ocular comfort. A follow-on product should not assume that simply removing benzalkonium chloride creates a meaningful market advantage. The benefit must be supported by comparative tolerability data, physician adoption, or payer differentiation.

Buffer system

The sodium citrate and sodium phosphate system controls pH and supports timolol stability. Buffer selection also affects:

• Ocular comfort after instillation.
• Timolol chemical stability.
• Preservative activity.
• Osmolality.
• Container closure compatibility.
• Potential precipitation or particulate formation.

A lower-buffer formulation may improve comfort but can reduce pH control during storage. A stronger buffer may improve stability while increasing stinging or altering preservative performance. The optimal strategy is a narrow pH and osmolality design supported by accelerated and long-term stability data.

Sodium hydroxide

Sodium hydroxide is used for pH adjustment. It is not a meaningful source of commercial differentiation, but its concentration and manufacturing control affect batch consistency and tolerability.

Purified water

Purified water is the vehicle. The key development issues are sterility assurance, endotoxin control, particulate control, and compatibility with the selected bottle and dropper system.

How does Istalol compare with generic timolol products?

Istalol competes against low-cost timolol maleate and timolol hemihydrate ophthalmic solutions. The main comparison is not pharmacologic novelty. It is delivery frequency, preservative profile, packaging, and patient persistence.

Product characteristic	Istalol strategy	Conventional generic timolol strategy
Active ingredient	Timolol maleate	Timolol maleate or hemihydrate
Typical strength	0.5%	0.25% or 0.5%
Dosing	Once daily	Often twice daily, depending on label
Preservative	Potassium sorbate	Frequently benzalkonium chloride
Packaging	Multidose ophthalmic bottle	Multidose ophthalmic bottle
Differentiation	Tolerability and adherence	Price and availability
Regulatory burden	NDA or 505(b)(2) positioning	ANDA if substitutable
Premium potential	Moderate, if clinically supported	Low

Once-daily administration can reduce treatment burden. The commercial question is whether the once-daily profile results from a protected formulation, a label-supported pharmacologic property, or simply clinical practice. A follow-on sponsor needs to establish its own labeling and bioequivalence position rather than rely on Istalol’s dosing schedule.

What formulation opportunities exist for Istalol competitors?

Preservative-free unit-dose timolol

A preservative-free unit-dose product is the clearest premium opportunity. It targets patients with ocular-surface disease, preservative sensitivity, chronic polypharmacy, contact-lens use, or repeated exposure to preserved glaucoma drops.

Advantages include:

• Elimination of chronic preservative exposure.
• Stronger positioning for ocular-surface tolerability.
• Potential use in patients who cannot tolerate preserved therapy.
• Compatibility with specialty ophthalmology channels.

Disadvantages include higher packaging cost, more waste, greater manufacturing complexity, and weaker convenience compared with a multidose bottle.

Preservative-free multidose bottle

Preservative-free multidose systems use container technologies that limit microbial ingress or deliver a sterile formulation through a one-way valve or specialized dispensing mechanism. These systems could provide the strongest combination of convenience and tolerability.

The main barriers are device qualification, extractables and leachables, microbial integrity, dosing uniformity, and higher cost of goods. The device may also create a separate intellectual-property estate.

Low-preservative multidose formulation

A potassium-sorbate or alternative low-irritation preservative formulation is closer to the Istalol model. It has lower manufacturing cost than a preservative-free system and can use conventional ophthalmic packaging.

The weakness is that the product may be viewed as only marginally different from existing generic formulations unless the sponsor can show improved comfort, lower ocular-surface toxicity, or superior treatment persistence.

Timolol combination products

Timolol is already used in fixed combinations with agents such as dorzolamide, brimonidine, and prostaglandin analogues. A once-daily, non-benzalkonium combination product could offer greater commercial value than standalone timolol.

The formulation burden is higher because each active ingredient can affect pH, solubility, preservative efficacy, viscosity, and stability. Combination products also face stronger competition from established branded and generic products.

Enhanced delivery systems

Potential delivery approaches include in situ gels, viscosity-enhanced solutions, emulsions, and sustained-release inserts. These could extend dosing intervals or reduce drainage after instillation.

Their commercial viability is limited by clinical-development cost and the need to demonstrate meaningful benefits over inexpensive eye drops. A modest reduction in dosing frequency is unlikely to support a premium without evidence of better pressure control, adherence, or tolerability.

What regulatory pathway applies to an Istalol follow-on product?

A conventional timolol ophthalmic solution may qualify for an abbreviated new drug application if it can meet the applicable sameness and bioequivalence requirements. A materially different formulation, preservative system, dosage form, or delivery device may require a 505(b)(2) application.

Product concept	Likely regulatory route	Key development issue
Same active, strength, dosage form, and comparable formulation	ANDA	Pharmaceutical equivalence and bioequivalence
Different preservative system	ANDA or 505(b)(2), depending on sameness	Local tolerability and preservative justification
Preservative-free multidose device	505(b)(2) or device-drug combination pathway	Device performance and microbial integrity
Unit-dose preservative-free solution	ANDA or 505(b)(2)	Packaging, stability, and usability
Sustained-release ocular system	505(b)(2) or full NDA	Clinical efficacy and delivery performance
Fixed combination with another active	ANDA or 505(b)(2)	Combination stability and comparative efficacy

FDA’s ophthalmic product guidance places emphasis on sterility, visible and subvisible particulate matter, container closure integrity, extractables and leachables, antimicrobial preservation, and ophthalmic product quality.[3]

What patents protect Istalol and when does exclusivity end?

Istalol’s original commercial protection was tied to its NDA, formulation attributes, and any listed patents covering the product or its use. Timolol itself is an old active ingredient, so molecule-level exclusivity is not available.

The practical exclusivity position is as follows:

Exclusivity category	Istalol position
New chemical entity exclusivity	Not available for timolol
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No material current protection identified
Formulation patents	Historically relevant; current enforceability depends on claim scope and expiration
Method-of-use patents	May affect particular glaucoma treatment claims, but generally narrow
FDA market exclusivity	Original NDA exclusivity has expired
Generic entry	Legally available subject to ANDA requirements and any unexpired listed patents

A commercial diligence review should distinguish expired formulation patents from live patents covering a specific preservative concentration, dosing schedule, container, or delivery system. Patent protection for a potassium-sorbate formulation would require claims that survive written-description, enablement, obviousness, and double-patenting challenges. Broad claims to timolol plus a conventional ophthalmic preservative would face substantial validity risk because the ingredients and formulation concepts are familiar in the field.

What is the Orange Book status of Istalol?

Istalol was approved under FDA NDA 021455. The original NDA pathway does not prevent generic entry after expiration of applicable exclusivity and patents. The Orange Book remains the controlling source for active patent listings and any current regulatory exclusivity associated with the application.[4]

For a potential ANDA sponsor, the strategic questions are:

• Whether NDA 021455 remains listed as the reference product.
• Whether any patents remain listed against the NDA.
• Whether a Paragraph IV certification is required.
• Whether the reference product is commercially available in the required strength.
• Whether FDA will accept the proposed product as pharmaceutically equivalent.
• Whether the proposed preservative and container system require a 505(b)(2) filing instead.

Because timolol ophthalmic products are widely available, a generic sponsor is more likely to face formulation and market-access issues than a fundamental active-ingredient patent barrier.

Which companies are challenging or competing with Istalol?

The relevant competitive set includes manufacturers of generic timolol maleate and timolol hemihydrate, branded glaucoma companies, and developers of preservative-free ophthalmic delivery systems.

Competitive categories include:

1. Generic ophthalmic manufacturers competing on acquisition cost.
2. Branded glaucoma companies selling preservative-reduced or preservative-free products.
3. Combination-product manufacturers using timolol with dorzolamide, brimonidine, or other pressure-lowering agents.
4. Specialty ophthalmic companies developing multidose preservative-free containers.
5. Compounding pharmacies serving patients with preservative intolerance, although compounded products do not provide the same regulatory substitution status as an FDA-approved product.

No biosimilar pathway applies. Istalol is a small-molecule ophthalmic drug, not a biologic. The relevant challenges are ANDA competition, 505(b)(2) reformulation, device differentiation, and physician preference.

What licensing and commercial opportunities exist?

The most attractive licensing targets are not rights to timolol itself. They are formulation and device technologies that can support a defensible product profile.

Potential assets include:

• Preservative-free multidose dispensing systems.
• Low-irritation ophthalmic preservatives.
• Sterile container closure technologies.
• Controlled-drop-size systems that reduce dose variability.
• In situ gel platforms.
• Combination ophthalmic formulations with improved stability.
• Regional rights for ophthalmic manufacturing and distribution.
• Contract manufacturing capacity for sterile ophthalmic products.

A license should be assessed against four commercial thresholds:

Criterion	Strategic test
Clinical value	Does the formulation improve comfort, adherence, or pressure control?
Regulatory efficiency	Can the product use an ANDA or 505(b)(2) pathway?
Manufacturing cost	Can the formulation be produced at generic-competitive cost?
Patent durability	Can the formulation or device support claims beyond routine optimization?

What generic launch scenarios exist?

Low-cost ANDA launch

This is the fastest route but offers limited differentiation. The product competes primarily through price, supply reliability, and payer contracts. Gross margins are likely to compress rapidly if multiple sponsors enter.

Premium preservative-reduced launch

This approach targets ophthalmologists who treat ocular-surface disease or preservative intolerance. The sponsor must support the positioning with comparative tolerability and adherence evidence.

Preservative-free specialty launch

This can command a higher price but requires expensive packaging, stronger specialty distribution, and a clear patient-selection strategy. Reimbursement may be more favorable when the product replaces poorly tolerated preserved therapy rather than generic timolol in all patients.

Combination-product launch

A timolol combination may capture greater value per prescription but faces established competitors and more complex clinical and manufacturing requirements.

How strong is the patent estate for an Istalol reformulation?

A new Istalol-related product could obtain meaningful protection if the claims are tied to a specific and reproducible technical solution. The strongest claim categories would likely cover:

• A defined preservative concentration range.
• A narrow pH and osmolality window linked to stability or tolerability.
• A specific container and dispensing system.
• A preservative-free multidose architecture.
• A stable combination formulation.
• A manufacturing process that controls degradation or particulate formation.
• A method of treating patients with documented preservative intolerance.

Weak claims would cover routine combinations of timolol, water, buffer, and a known preservative without unexpected results. Patent strength would improve if comparative data showed lower ocular-surface toxicity, improved stability, reduced dosing frequency, or superior patient persistence.

What revenue exposure and market economics apply?

Istalol-specific revenue is not reliably separable from broader timolol ophthalmic sales in public reporting. The addressable market is mature and price-sensitive. Revenue potential therefore depends on segmentation rather than molecule expansion.

The strongest commercial segments are:

• Patients requiring chronic glaucoma therapy who cannot tolerate benzalkonium chloride.
• Patients using multiple preserved ophthalmic products.
• Patients with dry eye or ocular-surface disease.
• Specialty ophthalmology practices seeking preservative-free options.
• Markets where branded or specialty ophthalmic products receive reimbursement.

The weakest segment is undifferentiated retail generic timolol. A conventional bottle with the same active ingredient and no meaningful tolerability or adherence advantage would likely face rapid price competition.

Key Takeaways

• Istalol is a once-daily 0.5% timolol maleate ophthalmic solution using potassium sorbate rather than benzalkonium chloride.
• The commercial value lies in preservative strategy, dosing convenience, and ocular-surface positioning, not in timolol exclusivity.
• Original NDA exclusivity has expired, and generic entry is available subject to Orange Book listings, product sameness, and any remaining enforceable patents.
• A conventional generic has limited pricing power.
• The strongest opportunities are preservative-free multidose systems, unit-dose products, and clinically supported low-irritation formulations.
• Patent protection is more credible for a defined formulation-device combination than for timolol plus routine excipients.
• Istalol has no biosimilar risk because timolol is a small molecule.
• A 505(b)(2) strategy may be appropriate for materially different preservatives, containers, delivery systems, or combination products.
• Commercial success depends on proving a measurable benefit over inexpensive generic timolol.

FAQs About Istalol Excipient and Commercial Strategy

Is potassium sorbate safer than benzalkonium chloride in glaucoma eye drops?

Potassium sorbate may offer a more favorable ocular-surface profile for some chronic-use patients, but comparative safety depends on concentration, pH, exposure frequency, and the full formulation.

Can a generic manufacturer copy Istalol’s potassium-sorbate formulation?

A manufacturer may develop a potassium-sorbate timolol product if it satisfies applicable regulatory requirements and does not infringe enforceable formulation, use, or device claims.

Is Istalol preservative-free?

No. Istalol uses potassium sorbate as an antimicrobial preservative. It is not equivalent to a preservative-free unit-dose or preservative-free multidose product.

Would a preservative-free timolol product receive automatic generic substitution?

Not necessarily. Substitution depends on FDA therapeutic-equivalence determinations, dosage-form and formulation equivalence, product labeling, and pharmacy law.

Can a new Istalol formulation obtain patent protection?

Yes, but protection is more likely for a specific formulation, delivery device, manufacturing process, or treatment method with evidence of an unexpected technical or clinical benefit than for a routine timolol ophthalmic composition.

References

1. U.S. Food and Drug Administration. (2004). Istalol (timolol maleate ophthalmic solution) prescribing information. NDA 021455.

2. Baudouin, C., Labbé, A., Liang, H., Pauly, A., & Brignole-Baudouin, F. (2010). Preservatives in eyedrops: The good, the bad and the ugly. Progress in Retinal and Eye Research, 29(4), 312-334. https://doi.org/10.1016/j.preteyeres.2010.03.001

3. U.S. Food and Drug Administration. (2023). Quality considerations for ophthalmic drug products: Guidance for industry. https://www.fda.gov/

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm